Teva, Mylan Back Plan For New Bellwether In Price-Fix MDL

Law360 (March 2, 2021, 6:53 PM EST) -- Mylan, Teva and Par Pharmaceuticals are among a group of generic-drug makers that told a Pennsylvania federal judge Monday they're fine with her plan to swap out a bellwether case in multidistrict litigation that accuses most of the generics industry of price-fixing.

The companies told U.S. District Judge Cynthia M. Rufe they share her inclination for scrapping the planned bellwether trial in a case brought by various state attorneys general that centers around Teva. Instead, the companies want Judge Rufe to select another case — one that focuses on Heritage Pharmaceuticals, which the court mentioned as a possibility less than a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!